Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (451-460 of 594) with videos related to

Pageof 60
Sort By:
Journal of the National Cancer Institute|April 5, 2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung CancerMasanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, et al.
Contemporary Clinical Trials|July 3, 2021
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trialAliana Guerrieri-Gonzaga, Davide Serrano, Parjhitham Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLCVincent K Lam, Jianjun Zhang, Carol C Wu, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
ISA101 and nivolumab for HPV-16<sup>+</sup> cancer: updated clinical efficacy and immune correlates of responseLuana Guimaraes de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 24, 2022
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-OophorectomyMeghna S Trivedi, Nadir Arber, Eitan Friedman, et al.
Cancers|March 13, 2024
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and ImmunotherapyKang Qin, Kaiwen Wang, Shenduo Li, et al.
Annals of Surgery|September 2, 2022
High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be DelayedErin M Bayley, Megan L Ivy, Jitesh B Shewale, et al.
Nature Medicine|April 24, 2019
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Frontiers in Immunology|December 28, 2023
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse eventsMehmet Altan, Quan-Zhen Li, Qi Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 10, 2024
Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional studyJames C H Chow, Jack Lee, Maria M P Lai, et al.
Pageof 60

Showing results (451-460 of 594) with videos related to

Sort By:
Pageof 60
Journal of the National Cancer Institute|April 5, 2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung CancerMasanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, et al.
Contemporary Clinical Trials|July 3, 2021
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trialAliana Guerrieri-Gonzaga, Davide Serrano, Parjhitham Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLCVincent K Lam, Jianjun Zhang, Carol C Wu, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
ISA101 and nivolumab for HPV-16<sup>+</sup> cancer: updated clinical efficacy and immune correlates of responseLuana Guimaraes de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 24, 2022
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-OophorectomyMeghna S Trivedi, Nadir Arber, Eitan Friedman, et al.
Cancers|March 13, 2024
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and ImmunotherapyKang Qin, Kaiwen Wang, Shenduo Li, et al.
Annals of Surgery|September 2, 2022
High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be DelayedErin M Bayley, Megan L Ivy, Jitesh B Shewale, et al.
Nature Medicine|April 24, 2019
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Frontiers in Immunology|December 28, 2023
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse eventsMehmet Altan, Quan-Zhen Li, Qi Wang, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 10, 2024
Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional studyJames C H Chow, Jack Lee, Maria M P Lai, et al.
Pageof 60